Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study

Ines Vaz-Luis, Romualdo Barroso-Sousa, Antonio Di Meglio, Jiani Hu, Rebecca Rees, Natalie Sinclair, Lindsey Milisits, Jose Pablo Leone, Michael Constantine, Meredith Faggen, Frederick Briccetti, Caroline Block, Kelly O'Neil, Ann Partridge, Harold Burstein, Adrienne G Waks, Lorenzo Trippa, Sara M Tolaney, Michael Hassett, Eric P Winer, Nancy U Lin, Ines Vaz-Luis, Romualdo Barroso-Sousa, Antonio Di Meglio, Jiani Hu, Rebecca Rees, Natalie Sinclair, Lindsey Milisits, Jose Pablo Leone, Michael Constantine, Meredith Faggen, Frederick Briccetti, Caroline Block, Kelly O'Neil, Ann Partridge, Harold Burstein, Adrienne G Waks, Lorenzo Trippa, Sara M Tolaney, Michael Hassett, Eric P Winer, Nancy U Lin

Abstract

Purpose: The use of growth factors adds considerable expense and some toxicity to adjuvant breast cancer chemotherapy. We tested the feasibility and safety of omitting routine peg-filgrastim use during the paclitaxel portion of the dose-dense doxorubicin-cyclophosphamide-paclitaxel regimen.

Patients and methods: This was a prospective, single-arm study in which patients 18 to 65 years of age who completed 4 cycles of dose-dense doxorubicin-cyclophosphamide for stage I-III breast cancer received paclitaxel 175 mg/m2 every 2 weeks. Peg-filgrastim was administered after paclitaxel only if patients had had febrile neutropenia in a prior cycle or at investigator discretion if patients had infections or treatment delays of > 1 week. Once a patient received peg-filgrastim, it was administered in all future cycles. The primary end point was the rate of paclitaxel completion within 7 weeks from cycle 1 day 1 to cycle 4 day 1. If ≥ 100 out of 125 patients completed 4 cycles of paclitaxel without dose delay, the regimen would be considered feasible.

Results: The enrollment goal of 125 patients was met. Median age was 46 years (range, 21-65 years), and 112 patients (90% [95% CI, 83% to 94%]) completed dose-dense paclitaxel within 7 weeks. Omission of peg-filgrastim was not causally related to noncompletion of paclitaxel in any patients. The most common reasons for dose reduction or delays were nonhematologic. One patient experienced febrile neutropenia but was able to complete paclitaxel on time. Eight patients (6.4%) received peg-filgrastim during the trial. Overall, peg-filgrastim was administered in only 4.3% of paclitaxel cycles.

Conclusion: Omission of routine peg-filgrastim during dose-dense paclitaxel according to a prespecified algorithm seems to be safe and feasible and was associated with a 95.7% reduction in the use of peg-filgrastim relative to the current standard of care.

Trial registration: ClinicalTrials.gov NCT02698891.

Figures

FIG A1.
FIG A1.
Study schema.

References

    1. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21:1431–1439.
    1. Bonilla L, Ben-Aharon I, Vidal L, et al. Dose-dense chemotherapy in nonmetastatic breast cancer: A systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst. 2010;102:1845–1854.
    1. Goetz MP, Gradishar WJ, Anderson BO, et al. NCCN guidelines insights: Breast cancer, version 3.2018. J Natl Compr Canc Netw. 2019;17:118–126.
    1. Burstein HJ, Parker LM, Keshaviah A, et al. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005;23:8340–8347.
    1. Lambertini M, Del Mastro L, Bellodi A, et al. The five “Ws” for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs) Crit Rev Oncol Hematol. 2014;89:112–128.
    1. Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: A systematic review. J Clin Oncol. 2010;28:2914–2924.
    1. Vaz-Luis I, Hughes ME, Cronin AM, et al. Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. Cancer. 2015;121:1937–1948.
    1. Shulman LN, Berry DA, Cirrincione CT, et al. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance) J Clin Oncol. 2014;32:2311–2317.
    1. Barroso-Sousa R, Paes FR, Vaz-Luis I, et al. Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study. Breast. 2016;30:136–140.
    1. Singh AK, Malhotra A, Lemke SM: A retrospective study of dose-dense adjuvant paclitaxel without G-CSF support in patients with breast cancer. J Clin Oncol [epub ahead of print on January 30, 2017]
    1. Sugarman S, Wasserheit C, Hodgman E, et al: A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma. Breast Cancer Res Treat 115:609-612, 2009 [Erratum: Breast Cancer Res Treat 126:267, 2011]
    1. Neulasta: Paying for Neulasta.
    1. Budd GT, Barlow WE, Moore HC, et al. SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol. 2015;33:58–64.
    1. Lyman GH, Poniewierski MS. A patient risk model of chemotherapy-induced febrile neutropenia: Lessons learned from the ANC Study Group. J Natl Compr Canc Netw. 2017;15:1543–1550.
    1. Barcenas CH, Niu J, Zhang N, et al. Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer. J Clin Oncol. 2014;32:2010–2017.
    1. Hurria A, Brogan K, Panageas KS, et al. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat. 2005;92:151–156.
    1. Hsieh MM, Everhart JE, Byrd-Holt DD, et al. Prevalence of neutropenia in the U.S. population: Age, sex, smoking status, and ethnic differences. Ann Intern Med. 2007;146:486–492.
    1. Haddy TB, Rana SR, Castro O. Benign ethnic neutropenia: What is a normal absolute neutrophil count? J Lab Clin Med. 1999;133:15–22.
    1. Nalls MA, Wilson JG, Patterson NJ, et al. Admixture mapping of white cell count: Genetic locus responsible for lower white blood cell count in the Health ABC and Jackson Heart studies. Am J Hum Genet. 2008;82:81–87.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する